research Dupilumab for a 5‐year‐old child with prurigo nodularis
Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Interleukins gene polymorphism in alopecia areata patients: a systematic review
Certain gene variations are linked to alopecia areata.
research Anagen Hair Follicles Transplanted into Mature Human Scars Remodel Fibrotic Tissue
Transplanted hair follicles can improve and remodel mature scars.
research Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
research Successful Treatment of Coexisting Alopecia Areata and Bullous Pemphigoid With Dupilumab: A Case Report
Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
research Olink proteomics analysis of scalp psoriasis reveals a cytokine storm inflammatory mainly related to bacterial-derived antigens
Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.
research ANALYSIS OF THE BACKGROUND LEVEL OF CYTOKINES M1 AND M2 OF THE MACROPHAGE PHENOTYPE IN PATIENTS WITH REVISION RHINOPLASTY AFTER THE USE OF THE DRUG PDRN
PDRN may reduce inflammation and complications in revision rhinoplasty for patients with high fibrinogen levels.
research Interleukin‐13 as a promising therapeutic target for alopecia areata associated with atopic dermatitis
Targeting Interleukin-13 could help treat alopecia areata linked with atopic dermatitis.
research 42905 Role of regulatory T and T-helper 17 cells in patients with acute diffuse and total alopecia
Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.
research 1617 Impact of type 2 cytokines on the keratinocytes-s. aureus interaction
Type 2 cytokines IL-4 and IL-13 increase skin's vulnerability to Staphylococcus aureus, which could be important for treating atopic dermatitis.
research 177 Chronic graft-versus-host disease exhibits distinct Th1-skewing and barrier abnormalities in the skin
Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research A 20-year retrospective clinicopathologic study on melanoma in Singapore
Bleach baths with 0.005% hypochlorite help manage atopic dermatitis by affecting skin cells and reducing itchiness.
research Alopesi areata hastalarında serum interferon-gama, tümör nekrozis faktör-alfa, interlökin-13, interlökin-17 ve transforming growth faktör-beta düzeylerinin değerlendirilmesi
Atopy and altered T cell functions contribute to Alopecia Areata.
research Clinical Snippets
Ferulic acid helps stabilize vitamins C and E for better skin protection from the sun, certain compounds may promote hair growth, atopic dermatitis patients have lower skin defense molecules, older men are more likely to get a type of skin cancer, and a substance called relaxin may prevent age-related skin thickening.
research Dupilumab and alopecia: A Janus effect
Dupilumab can both heal and cause hair loss.
research Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report
Dupilumab may help regrow hair in people with atopic dermatitis.
research Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
A medication for skin rash also unexpectedly treated hair loss in a patient.
research 1117 PX-12 inhibits NLRP3 inflammasome activation to treat psoriasis
PX-12 may help treat psoriasis by blocking inflammation and cell death.
research IL-17 inhibition: is it the long-awaited savior for alopecia areata?
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
research 034 Characterization of novel TMEM173 mutation causing a lupus- and SAVI-like phenotype, modified by polymorphisms in TMEM173 and IFIH1
A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
research Inhibition of a signaling modality within the gp130 receptor enhances tissue regeneration and mitigates osteoarthritis
Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing
A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
research IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research 1112 An innovative phase 1b trial demonstrating proof-of-pharmacology for two novel IRAK4-inhibitors using a local (Imiquimod) and systemic (LPS) driven immune response
Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.